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Introduction
Discovery of ass’ milk (AM) properties find
its roots in antiquity, when doctors recommended it
to treat several afflictions, due to its healing and
cosmetic virtues. Even Hippocrates (460-370 BC)
prescribed it for several purposes ranging from poi-
soning to fevers and infectious disease, from edema
to wounds healing, from nose bleeds to liver trou-
bles(1). According to tradition, Cleopatra, Queen of
Ancient Egypt (69-30 BC), took baths in AM to
preserve her beauty and softness of her skin; no less
than 700 she-asses (daily milk production of a
female ass or donkey fluctuate between 0.2 to 0.3
liters) were needed to provide the quantity of milk
necessary for her daily bath. Similar baths were
also performed by Poppaea Sabina (30-65 AD),
Roman Emperor Nero’s second wife(2).
Possible use of AM was proposed by Pliny the
Elder (23-79 AD), in his encyclopedic work,
Naturalis Historia,  to fight fever, fatigue, eye
strain, weakened teeth, face wrinkles, poisonings,
ulcerations, asthma and certain gynecological trou-
bles (2). Benefits of AM were also reported by
Georges-Louis Leclerc, Comte de Buffon (1707-
1788), in his Histoire Naturelle(3). First reports as
possible substitute for breast milk were datable at
the beginning of the 20th century. Dr. Charles
Porcher (1872-1933) of the Lyon National
Veterinary Institution testimony, in 1928, showed
that the practice was still used, to a lesser extent, in
the interwar years(4). Nowadays AM is largely used
in the manufacture of soaps and moisturizers, but
new evidence show its possible medical use , espe-
cially to treat infants and children with cow's milk
(CM) protein allergy (CMPA).
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ABSTRACT
Several studies has recently enlightened therapeutic use of ass’ milk (AM) due to its special composition and nutritional prop-
erties, which are very close to human one. This feature makes ideal substitute of breast milk, whenever the mother cannot or will
not breastfeed, or the child is intolerant to cow's milk (CM), providing the nutritional and health needs of the infant. The authors
reviewed the literature about AM tolerance, safety and efficacy in the treatment of infants and children with a food allergy, i.e. CM
protein allergy (CMPA). In all the reviewed studies, AM was well tolerated and acceptable, due to its palatability. Researchers
enrolled children over 6 months of age, who did not have an exclusive milk diet, and/or had medium-chain triglycerides added.
Overall data showed an adequate increase in auxological parameters measured after several months of AM consumption. Finally,
potential cross-reactivity between AM protein and CM proteins must be considered. These results suggest that AM might be consid-
ered nutritionally adequate in infants and children with CMPA or multiple food allergies, included CMPA.
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We reviewed international literature, using
PubMed, and the searching terms “ass’ milk”, “don-
key’s milk” and “cow’s milk protein allergy”, high-
lighting how AM may be a valid nutritional support
for patients affected with CMPA, and it is able to
ensure adequate increase in auxological parameters,
filling nutritional deficiencies of these subjects.
Biochemical properties of ass’milk 
AM chemical composition and protein con-
tent, together with its low allergic potential , have
made it, since a long time, a great replacement of
breast milk. AM digestibility is better than CM and
similar to human one, due to the high whey protein
and the low casein content, so it may be used in
infants and children suffering from CMPA. A
Northwest China study, taken on by Guo et al.,
aimed to investigate the chemical composition,
nitrogen fraction distribution, and amino acid (AA)
profile of milk samples obtained during lactation
from donkeys. The study pointed-out that AM con-
tained 9.53% total solids, 1.57% protein, 1.16% fat
and 6.33% lactose, and 0.4% ash; all these data
makes it more similar to human and mare milk than
to other mammals (Table 1). pH and density proved
constant in all the samples collected during lacta-
tion, whereas protein and ash content displayed an
apparent negative trend. Moreover, it has been
proved that lactose content exhibited an increase
during first 120 days postpartum, followed by a
decrease. Fat content showed wide variability,
whereas a small one was pointed-out to casein,
whey protein and AA. A casein to whey protein
ratio of 52:37 was evidenced, between the lower
human milk and the higher CM value. AM proved
rich in β-lactoglobulin and lysozyme at Sodium
dodecyl sulfate-PolyAcrylamide Gel
Electrophoresis (SDS-PAGE). The percentage of 8
essential AA in AM protein was 38.2%, higher than
those of cow and mare milk. Moreover AM had
higher levels of serine (6.2%), glutamic acid
(22.8%), arginine (4.6%), and valine (6.5%) and a
lower level of cysteine (0.4%) (5-8). Lately an
extensive proteomic study and a detailed compara-
tive analysis among the protein fractions (i.e. casein
and whey proteins) of AM, CM and human milk
has been conducted in Italy. These studies reported
detailed protein composition and structural features
and explained molecular reasons of AM hypoaller-
genic quality. Analyzing AM allergenic properties
with those of CM, it seems that the difference lies
in the significant differences between primary
structures of proteins, which determine deep diver-
gence between the amino acid sequences of IgE-
binding linear epitopes of CM allergens and the
corresponding domains present in donkey’s milk
proteins(9-14). In regard to lipid fraction, AM has been
indicated as a nutraceutical food due to some bioac-
tive compounds, which are able to modify, directly
or indirectly, the intestinal environment and immu-
nity playing a role in the prevention and treatment
of some pathologies. Chiofalo et al., analyzing AM
triacylglycerol (TAG) composition, identified 72
TAGs, and examined similarities and differences
among ass and human milk TAGs fraction; a parti-
tion number values from 30 to 50 was enlightened.
Short-chain fatty acids (FAs) are not well represent-
ed in human milk while the PN values range
between 36 and 52. 
Furthermore ω3 and ω6 FAs amount in AM is
larger than human milk ones, this last contains only
significant amounts of ω6 FA (linoleic). AM high
polyunsaturated fatty acids (PUFA) n-3 content,
and especially its low n-6/n-3 ratio, acquires partic-
ular interest in subjects with CMPA. In addition,
both donkey and human milk present the saturated
FA preferably on the sn-2 position. Aforesaid,
together with the relatively high content of medi-
um-chain triglycerides, explain the increasing inter-
est toward AM as an alternative food for a hypoal-
lergenic diet in humans: as a matter if fact all this
results in high bioavailability and digestibility of
AM lipids, despite their low amount(15-18). 
A late study of La Torre et al. studied amines
composition of 13 AM samples by high perfor-
mance liquid chromatography atmospheric pressure
chemical ionization mass spectrometry (HPLC-
APCI-MS): 8 bioactive amines (histamine, tyra-
mine, tryptamine, 2-phenylethylamine, cadaverine,
putrescine, spermidine and spermine) were found:
among these, putrescine, spermine and spermidine
proved to be the most represented even if their con-
centration were lower than the correspective found
in mature human, cow and sow milk(19).
Ass’milk and food hypersensitivity 
One of the most frequent causes of poor
absorption and growth retardation in unweaned
children during the first months after birth is defi-
nitely food hypersensitivity. CMPA alone seems to
affect 2-7.5% of the general population and its
diagnostic incidence is increasing (1:200 versus
1:7.500 recorded in 1948). Nevertheless, CM pro-
teins are just some of the many possible allergens
triggering food hypersensitivity reactions: rice, soy
and hen’s egg are the most reported ones. These
rarer food hypersensitivities are reported to be more
frequent in patients allergic to CM protein first, cre-
ating a multiple food hypersensitivity. Remarkable
progress have been made in parenteral nutrition
leading to substantial prognosis improvement; nev-
ertheless the need to reintroduce alimentation per os
as soon as possible is universally accepted, to stim-
ulate the functional recovery of the damaged intes-
tine. Breast-feeding seems the safest way to gain
this goal, even if, obviously, human milk is not
often readily available; other solutions are needed.
On the other hand, severe hypersensitivity reactions
might be evoked by formulas containing soy pro-
tein or by hydrolyzed protein ones. Consequently,
multiple food hypersensitivity, including CMPA
could be treated by the use of AM: this might offer
an important and satisfactory solution. Its above
reported composition and nutritional properties
make it a valid alternative especially considering its
ability to integrate fat intake in CMPA patients.
Infants seems to like it more than other substitute
due to its high lactose concentration and, qualita-
tively, this is preferable to semi-elemental formulas,
protein hydrolysates or soy formulas, which contain
carbohydrates other than lactose. This high lactose
content stimulates calcium intestinal absorption
leading to better bone mineralization in the infant.
Other point which makes AM a eligible substitute is
the renal solutes load, mainly determined by the
dietary amount of proteins and inorganic sub-
stances, which is substantially very similar in both
breast-fed infants and AM fed ones. This represents
a considerable advantage, considering the lower fat,
and obviously caloric, content of AM compared to
CM(20,21). Considering the above mentioned, it could
be concluded that, in areas where it is readily avail-
able, AM is certainly preferable to a lactose-free
artificial dietary milk.
In 1992, Iacono et al., analyzed the clinical
data of 9 patients with multiple food hypersensitivi-
ty, including CMPA, treated over the last 2 years,
and initially re-fed exclusively with AM (Table 2).
The patients who referred severe symptoms of
CMPA did not improve their clinical condition, at
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Composition of donkey’s, mare’s, human and cow’s milk (g/100 g)
composition donkey mare human cow
pH 7.0-7.2 7.18 7.0-7.5 6.6-6.8
Total Solids g/100 g 8.8-11.7 9.3-11.6 11.7-12.9 12.5-13.0
Protein g/100g 1.5-1.8 1.5-2.8 0.9-1.7 3.1-3.8
Fat g/100g 0.3-1.8 0.5-2.0 3.5-4.0 3.5-3.9
Lactose g/100g 5.8-7.4 5.8-7.0 6.3-7.0 4.4-4.9
Casein Nitrogen g/100 g 0.64-1.03 0.94-1.2 0.32-0.42 2.46-2.80
Whey protein g/100 g 0.49-0.80 0.74-0.91 0.68-0.83 0.55-0.70
Non-protein nitrogen g/100 g 0.18-0.41 0.17-0.35 0.26-0.32 0.1-0.19
Casein Nitrogen % 47.28 50 26.06 77.23
Whey protein % 36.96 38.79 53.52 17.54
Non-protein nitrogen % 15.76 11.21 20.42 5.23
Table 1: Composition of donkey’s, mare’s, human and cow’s milk
From Guo HY, Pang K, Zhang XY, Zhao L, Chen SW, Dong ML, Ren FZ. Composition, physiochemical properties,
nitrogen fraction distribution, and amino acid profile of donkey milk. J Dairy Sci 2007; 90: 1635-43 (modified).
successive attempts using milk containing soy pro-
tein and/or a semi-elemental formula due to the
onset of hypersensitivity also to these allergens.
After a short period of parenteral alimentation, the
infants were re-fed per os with AM (250 mL/kg/
day) plus medium chain triglycerides (40 mL/L
milk). All patients tolerated this kind of alimenta-
tion. No negative clinical reaction was recorded and
during hospitalization average weight increase was
39.8 g/day. The follow-up of patients showed that
AM was well tolerated up to an age ranging from
15 to 20 months(22). The same authors in another ret-
rospective study (Table 2), evaluated the clinical
characteristics and the long-term outcome of treat-
ment with AM of patients affected with CMPA
and/or multiple food hypersensitivity, including
CMPA, and hydrolyzed protein (HP) intolerance,
focusing their attention on its nutritional value. In
the past, intolerance to HP formulas has been con-
sidered, a very rare event, but late reports hypothe-
sized that it might not be so uncommon; however,
very few data have been published about the natural
history of CMPA subjects intolerant to HP milk for-
mulas too. In the study the authors reported clinical
characteristics and the follow-up (median period of
about 4 years) of 21 CM- and casein hydrolysate
(CH) formula-intolerant infants, treated with an
AM-based diet, and, as controls, 70 CM-intolerant
infants, treated with CH milk-based diet. Double-
blind placebo-controlled challenge positivity have
been considered the preliminary point to define CH
formula-intolerance and intolerance to other foods.
Formal CM-challenges were conducted at yearly
intervals until tolerance was demonstrated. The
study demonstrated that the patients intolerant to
extensively CH formula had a more severe clinical
framework than the patients successfully treated
with this same formulas. CM-tolerance at the end of
the study, after a median follow-up period of 4
years, was achieved by 52% of the CM- and CH-
intolerant patients, whereas 78% of CH-tolerant
patients became CM-tolerant at the end of the
study. Furthermore, the median age CH-intolerant
patients achieved CM-tolerance was significantly
higher than the CH-tolerant ones. These data could
be explained valuing the higher hyperactivity of
CH-intolerant subjects, which seems to be con-
firmed by the higher frequency (100%) of a coex-
isting multiple food hypersensitivity (i.e. to soy,
goat’s and sheep’s milk, soy, oranges, tomatoes and
fish). Intolerance to extensively hydrolyzed protein
seems to be just the epiphenomenon of an elevated
reactivity which is the basis of a more prolonged
and severe food intolerance history. As a matter of
fact high serum IgE levels can be detected in two-
thirds of the CH-intolerant patients. In addition, the
authors pointed out a higher frequency and more
elevated levels of total serum IgE and specific IgE
to CM antigens than in CH-intolerant patients than
in their tolerant counterpart. Whenever treated with
an AM diet, the subjects gained satisfying weight
and height and, just in 1 year of CM-free diet, the
more common blood nutritional parameters fall
back to the normal range. Besides, the authors did
not observe any difference in growth parameters
during the follow-up period between the AM and
the CH-milk treated group. This must be considered
in the light of multiple food intolerance coexis-
tence: in the CH-milk treated group only 14%
patients showed multiple food intolerance, whereas
all infants treated with AM suffered from this
comorbidity; this greatly limited food choice. The
study demonstrated that AM is a safe solution even
in infants in whom hydrolyzed-milk formulas had
failed. For the latter, L-aminoacid based formulas
have been recently used and achieved good results,
providing satisfactory growth recovery. Finally, but
not of minor importance is the taste and the cost:
hydrolyzed formula products have an unpleasant
taste and are quite expensive, so the use of AM
might be encouraged also in CMPA CH-tolerant
subjects(23). 
A fairly recent prospective study by Monti et
al. (Table 2), investigated in vivo tolerance, palata-
bility and nutritional adequacy of AM in a popula-
tion of 46 infants and children with CMPA and
other food allergies (mainly soy, wheat, egg and
fish), for whom maternal milk was not available
and no available CM substitute could be used. CMP
elimination diet, followed by double-blind, place-
bo-controlled food challenge (DBPCFC) have been
used to diagnose CMPA. Before food challenge,
CM proteins skin prick tests (SPT) and RAST were
performed too. An IgE-mediated CMPA was proved
in 33 children which were CM protein SPT- and/or
RAST-positive. The remaining 13 were classified as
non-IgE-mediated CMPA. AM challenge proved
positive in 8 children (17.4%), whereas the remain-
ing 38 (82.6%) both liked and tolerated AM at the
challenge and throughout the follow-up period. AM
was tolerated by 26 (78.8%) of IgE-mediated
CMPA children and by 13 of non-IgE-mediated
CMPA ones. Catch-up growth (in terms of
length/stature and weight and Z-scores for
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length/stature and weight increases) was observed
in all subjects characterized by growth deficit dur-
ing CM protein challenge. No IgE crossreactivity
versus AM proteins was enough strong or specific
to be considered. Also Monti et al. identified AM as
a valid alternative, both in terms of palatability and
weight-height gain, in IgE-mediated and non-IgE-
mediated CMPA(24-26). Vita et al., in 2007 (Table 2),
relying on the frequent association between CMPA
and atopic dermatitis (AD), followed, in frequency,
by urticaria/angioedema, gastrointestinal symp-
toms, wheezing and asthma, carried out a crossover
randomized-controlled trial to objectively compare
the tolerance of AM, with goat’s milk (GM), used
as the control. Their purpose was to analyze effect
of AM based diet in the treatment of CMPA-related
AD. As control diet GM was chosen because it is
widely used as a CM substitute in clinical practice.
Twenty-eight children suffering from CMPA and
AD were enrolled in the study. Randomization was
performed among patients to include in AM or GM
diet group for 6 months, then they were switched to
the other for further 3 months. The severity scoring
of atopic dermatitis (SCORAD) index (SI) and a
visual analogue scale (VAS) were blindly evaluat-
ed. At the end of the study, food challenges with
GM and AM were performed. Two children from
the GM group dropped out after randomization and
26 completed the study. A significant improvement
of SI and VAS symptoms (p<0.03 vs. baseline and
inter-group) was always obtained by AM diet,
whereas GM had no statistically significant clinical
effects. At the end of the study 23 of 26 children
had a positive food challenge with GM, while just
one of 26 had with AM. The study proved  that AM
is tolerated by 88% of children with CMPA deter-
mining a significant improvement in AD. On the
contrary, in all patients treated with GM, symptoms
remained unchanged or even worsened. In particu-
lar, all children previously on AM diet had a relapse
of AD after switching to GM. Extremely relevant,
to our advice, is the sudden positivity to DBPCFC
for GM, at the end of the study, in the most of the
patient although none of them had been previously
fed with GM-containing foods. We speculate that
this may be due to the GM protein profile which is
quite similar to CM, as confirmed by a SDS-PAGE
analysis, performed on both kind of milk. Even if
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Table 2: Ass’s milk in the treatment of cow’s milk protein allergy and others food allergies.
AM: ass’s milk
CM: cow’s milk
CMPA: cow’s milk protein allergy
this was not the first report documenting that AM
could be an appropriate alternative to CM, this has
surely been the first to demonstrate that AM is bet-
ter tolerated than GM, which is still widely used. In
conclusion, our revision results suggest that GM
should not be used in children with CMPA and AD,
whereas AM, if available, may be an effective and
safe alternative(27). 
Tesse et al., in 2009 (Table 2), evaluated 30
children with suspected CMPA. Skin prick tests,
using fresh CM, AM, pear juice and other common
food and aero-allergens, and DBPCFC to CM pro-
teins were performed too. Patients, who were con-
firmed suffering from CMPA, received fresh AM in
open challenge. Specific serum CM and AM pro-
tein IgE, as well as blood biochemical parameters
were assessed. All subjects at entry and after 4-6
months of AM intake underwent to auxological
evaluation (standing height, weight and BMI). Of
the 30 subjects, 25 were considered suitable for the
study, and 24 (96%) of this last  tolerated AM at the
food challenge. IgE-mediated CMPA was proved in
22 AM tolerant children, while 2 had non-IgE-
mediated disease. AM was included in tolerant chil-
dren diet balancing of age demand. Auxological
data in all patients improved by the end of the
study, while blood biochemical parameters did not
vary during the follow-up. These data confirm a
high rate of AM tolerance in children with moder-
ate CMPA symptoms, and demonstrated that AM
seems to be nutritionally adequate in subjects on a
relatively free diet(28). Lately Pilla et al. examined
101 half-udder AM samples determining hygienic
and health characteristics through somatic cell
count (SCC), bacteriological analysis and total bac-
teria count (TBC). Antimicrobial susceptibility was
tested in all the major pathogens, and
Staphylococcus aureus isolates were further geno-
typed by nanoarray analysis. Whey lysozyme and
N-acetyl-β-D-glucosaminidase (NAGase) activities
were also assessed, they showed very low TBC
(<250 CFU/ml) and SCC (<50.000 cells/ml) values
and a minor prevalence of pathogens:
Staphylococcus aureus was only isolated from 5
milk samples (3 animals), Streptococcus equi from
2 samples and Streptococcus equisimilis from a sin-
gle sample. No resistance against the classes of
antibiotics of veterinary use could be proved. None
of the Staphylococcus aureus isolates was found
positive to harbor genes coding for any enterotoxin,
toxic-shock syndrome toxin, or antibiotic resis-
tance. Lysozyme levels were always very high
(4.000-5.000 U/ml), while, during the last part of
lactation, NAG values were quite low (<50 U/ml).
This study confirmed the low prevalence of intra-
mammary infections in donkeys and the absence of
food-borne pathogens, suggesting AM safeness pro-
file, if the ass mammary gland is healthy and the
animals are milked in proper hygienic conditions(29).
In contrast to the above mentioned study, Conte et
al., in 2008, described, in strains from 50 samples
of AM in Sicily, isolation of two Enterobacter
sakazakii (ES). Isolates revealed a multiple resis-
tance profile, including fluoroquinolones, common-
ly used to treat animal infections. In 2002, the
International Commission for Microbiological
Specifications for Foods (ICMFS) ranked ES as a
‘severe hazard for restricted populations, life threat-
ening or substantial chronic sequelae of long dura-
tion’. ES (‘yellow pigmented Enterobacter cloa-
cae’) has been found among the common foodborne
pathogens, such as Listeria monocytogenes, etc.
The genus Enterobacter was associated with the
phytic flora and it was supposed that the principal
environmental sources of ES are water, soil and
vegetables, and a secondary contamination media
may be vectors such as flies and rodents; neverthe-
less the organism is considered ubiquitous. Birth
canal ES contamination or post-birth environmental
sources might be responsible of neonatal infections.
Moreover, several neonatal meningitis cases
may have some relationship with the most common
newborn gastrointestinal disease associated with
bacterial pathogens: necrotizing enterocolitis.
Neonatal pathologies also include bacteremia,
wound exudates, appendicitis, and conjunctivitis; in
adults the organism usually causes bacteremia. A
possible cause of infection and illness, including
severe disease which can lead to serious sequelae
and death, in infants can be due to intrinsic ES and
Salmonella contamination of powered infant formu-
la. No link has been established between illness and
other microorganisms in powered formula, although
such a link was considered plausible for other
Enterobacteria. This is the first report of ES from
AM and their recovery is noteworthy, especially
because infants consume raw milk. Even this is a
topic of great importance, the uncertainty about ES
infectious dose and its antimicrobial susceptibility
profile should be adequately valued. A full risk
assessment of the organism will require greater
knowledge of its presence in food, especially the
ones used to feed neonates and infants(30).
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Conclusions
As a result of careful analysis of literature, is
beyond doubt the AM usefulness as substitute for
breast milk in infants suffering from CMPA or mul-
tiple food allergies included CMPA. The authors
have performed studies confirming the high toler-
ance of this product by the patients either with the
IgE- and non-IgE-mediated CMPA. Another impor-
tant factor is certainly its palatability, which make it
more appetizing than hydrolyzed formulas. Despite
AM protein composition is similar to human milk,
is a low-calorie food. For this reason, in some stud-
ies the researchers enrolled children older than 6
months, who did not have an exclusive milk diet,
and/or added medium chain triglycerides to the
diet. Overall data showed an adequate increase in
auxological parameters (i.e. weight, length/stature
and Body Mass Index, BMI), measured after sever-
al months of AM administration. It is possible to
argue that the effect of AM on growth is related to
its ability to fill some nutritional gaps present in the
diet of treated subjects. Moreover, during and after
AM administration period, patients’ biochemical
and metabolic blood parameters did not vary.
Nevertheless, all the studies suggest that a longer
follow-up is needed in order to achieve reliable
results. Finally, AM proteins potential cross-reactiv-
ity with CM proteins must be considered, suggested
by the above mentioned studies that sometimes
reported severe reactions to AM in their study
cohorts. However, taken together, all these results
suggest that AM might be considered nutritionally
adequate in children with CMPA or multiple food
allergies included CMPA. Another critical point
which should be stressed, is lack of easy AM avail-
ability even in countries where donkeys are very
common, turning its costs higher than CM and
hydrolyzed formulas and making this food, espe-
cially for poorer patient families, difficult to access.
For this, further studies would be needed to confirm
AM usefulness in filling the nutritional gap of
CMPA patients and make it considered among
medicaments approved by public health.
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